Phase 1/2 × Completed × Leukemia, Biphenotypic, Acute × Clear all
NCT00423514 2022-12-27

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
38 enrolled 12 charts
NCT00006251 2020-01-21

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Completed
21 enrolled
NCT00245037 2017-09-27

Bu Flu TBI

OHSU Knight Cancer Institute

Phase 1/2 Completed
147 enrolled 19 charts
NCT00003425 2013-04-26

Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect

University of Kentucky

Phase 1/2 Completed
25 enrolled
NCT00003406 2013-03-26

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
30 enrolled
NCT00823524 2013-02-20

Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer

Asan Medical Center

Phase 1/2 Completed
47 enrolled
NCT00006225 2012-06-06

Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer

Northwestern University

Phase 1/2 Completed
NCT00010283 2010-04-02

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

Fred Hutchinson Cancer Center

Phase 1/2 Completed